ArticleJournal of inflammation research2026
Development and Validation of a Nomogram Based on Advanced Lung Cancer Inflammation Index for Predicting Overall Survival in Non-Surgical Esophageal Squamous Cell Carcinoma.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite advancements in multidisciplinary treatment strategies, long-term survival of esophageal squamous cell carcinoma (ESCC) patients remain suboptimal. Identifying novel prognostic biomarkers is essential for individualized treatment and surveillance approaches. The Advanced Lung Cancer Inflammation Index (ALI), an integrative biomarker reflecting nutritional, inflammatory, and immune status, has emerged as a potential predictor of prognosis. However, its association with overall survival (OS) in non-surgical ESCC patients remains poorly understood. This study aims to evaluate the prognostic value of ALI in ESCC patients undergoing radical radiotherapy and to develop a predictive nomogram to support clinical decision-making. Patients and Methods: We retrospectively analyzed pre-radiotherapy ALI values of 266 ESCC patients treated from January 2017 to October 2022. A restricted cubic spline (RCS) model explored the link between continuous ALI levels and survival risk. Univariate and multivariate Cox proportional hazards models were used to identify independent predictors of OS, and a nomogram was constructed to predict 1 - year, 3 - year, and 5 - year OS probabilities. Results: RCS analysis stratified patients into low (≤227.5), medium (227.5-570.4), and high (>570.4) ALI risk groups. Kaplan-Meier curves showed significant differences among the three groups, with lower ALI values associated with poorer prognosis (P = 0.0057). Multivariate analysis confirmed that ALI, radiation dose, T stage, and N stage were independent predictors of OS. A forest plot precisely quantified each variable's prognostic contribution. The developed nomogram exhibited moderate to high predictive accuracy, as reflected by the area under the time-dependent ROC curves. Decision curve analysis (DCA) indicated a net clinical benefit at 1 - year, 3 - year, and 5 - year time points. Conclusion: ALI is an independent prognostic factor for overall survival in non-surgical ESCC patients treated with radical radiotherapy. The ALI-based nomogram demonstrates good predictive performance and may serve as a useful tool for personalized risk stratification and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.